KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs

Journal of Clinical Investigation

Volumn 123, Issue 2, 2013, Pages 727-739

  Tzatsos, Alexandros ^a,b   Paskaleva, Polina ^a   Ferrari, Francesco ^c   Deshpande, Vikram ^a   Stoykova, Svetlana ^a   Contino, Gianmarco ^a   Wong, Kwok Kin ^b,d   Lan, Fei ^e   Trojer, Patrick ^e   Park, Peter J ^c   Bardeesy, Nabeel ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Harvard Medical School Center for Biomedical Informatics   (United States)

^d DANA FARBER HARVARD CANCER CENTER   (United States)

^e Department of Structural Biology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BMI1 PROTEIN; HISTONE DEMETHYLASE; K RAS PROTEIN; KDM2B PROTEIN; MYC PROTEIN; POLYCOMB GROUP PROTEIN; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN P53; RETINOBLASTOMA BINDING PROTEIN 2; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GRADING; CANCER STAGING; CARCINOGENICITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMATIN; CONTROLLED STUDY; DOWN REGULATION; EPIGENETICS; GAIN OF FUNCTION MUTATION; GENE CONTROL; GENE REPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IN VIVO STUDY; LOSS OF FUNCTION MUTATION; METASTASIS; MITOCHONDRION; MOUSE; NONHUMAN; ONCOGENE MYC; OXIDATIVE PHOSPHORYLATION; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SOMATIC CELL; TUMOR DIFFERENTIATION; UPREGULATION;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; EPIGENESIS, GENETIC; F-BOX PROTEINS; HUMANS; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; MICE; MICE, SCID; OXIDOREDUCTASES, N-DEMETHYLATING; PANCREATIC NEOPLASMS; POLYCOMB-GROUP PROTEINS; PROTO-ONCOGENE PROTEINS P21(RAS); TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84873343056     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI64535     Document Type: Article

References (48)

1. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605-1617.
2. Jones S, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321(5897):1801-1806.
3. Singh A, et al. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell. 2009;15(6):489-500.
4. Collisson EA, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17(4):500-503.
5. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med. 2011;17(3):330-339.
6. Chi P, Allis CD, Wang GG. Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer. 2010;10(7):457-469.
7. Kampranis SC, Tsichlis PN. Histone demethylases and cancer. Adv Cancer Res. 2009;102:103-169.
8. Van Haaften G, et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet. 2009;41(5):521-523.
9. Rui L, et al. Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell. 2010;18(6):590-605.
10. Pfau R, Tzatsos A, Kampranis SC, Serebrennikova OB, Bear SE, Tsichlis PN. Members of a family of JmjC domain-containing oncoproteins immortalize embryonic fibroblasts via a JmjC domaindependent process. Proc Natl Acad Sci U S A. 2008;105(6):1907-1912.
11. Kottakis F, Polytarchou C, Foltopoulou P, Sanidas I, Kampranis SC, Tsichlis PN. FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 pathway. Mol Cell. 2011;43(2):285-298.
12. Tzatsos A, Pfau R, Kampranis SC, Tsichlis PN. Ndy1/KDM2B immortalizes mouse embryonic fibroblasts by repressing the Ink4a/Arf locus. Proc Natl Acad Sci U S A. 2009;106(8):2641-2646.
13. Tzatsos A, et al. Lysine-specific demethylase 2B (KDM2B)-let-7-enhancer of zester homolog 2 (EZH2) pathway regulates cell cycle progression and senescence in primary cells. J Biol Chem. 2011;286(38):33061-33069.
14. He J, Kallin EM, Tsukada Y, Zhang Y. The H3K36 demethylase Jhdm1b/Kdm2b regulates cell proliferation and senescence through p15 (Ink4b). Nat Struct Mol Biol. 2008;15(11):1169-1175.
15. Wang T, et al. The histone demethylases Jhdm1a/1b enhance somatic cell reprogramming in a vitamin-C-dependent manner. Cell Stem Cell. 2011;9(6):575-587.
16. He J, Nguyen AT, Zhang Y. KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia. Blood. 2011;117(14):3869-3880.
17. Maitra A, Hruban RH. Pancreatic cancer. Annu Rev Pathol. 2008;3:157-188.
18. Aguirre AJ, et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 2003;17(24):3112-3126.
19. Hingorani SR, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003;4(6):437-450.
20. Corcoran RB, et al. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res. 2011;71(14):5020-5029.
21. Bardeesy N, et al. Both p16 (Ink4a) and the p19 (Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A. 2006;103(15):5947-5952.
22. Ben-Porath I, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet. 2008;40(5):499-507.
23. Kondo Y, et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet. 2008;40(6):741-750.
24. Wilson BG, et al. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell. 2010;18(4):316-328.
25. Shain AH, et al. Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. Proc Natl Acad Sci U S A. 2012;109(5):E252-E259.
26. Kim J, et al. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell. 2010;143(2):313-324.
27. Ougolkov AV, Bilim VN, Billadeau DD. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin Cancer Res. 2008;14(21):6790-6796.
28. Toll AD, et al. Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma. Hum Pathol. 2010;41(9):1205-1209.
29. Kleer CG, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A. 2003;100(20):11606-11611.
30. Yu J, et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res. 2007;67(22):10657-10663.
31. Li L, Greer C, Eisenman RN, Secombe J. Essential functions of the histone demethylase lid. PLoS Genet. 2010;6(11):e1001221.
32. Secombe J, Li L, Carlos L, Eisenman RN. The Trithorax group protein Lid is a trimethyl histone H3K4 demethylase required for dMyc-induced cell growth. Genes Dev. 2007;21(5):537-551.
33. Sharma SV, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141(1):69-80.
34. Lin W, et al. Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1. Proc Natl Acad Sci U S A. 2011;108(33):13379-13386.
35. Ram O, et al. Combinatorial patterning of chromatin regulators uncovered by genome-wide location analysis in human cells. Cell. 2011;147(7):1628-1639.
36. Sanchez C, Sanchez I, Demmers JA, Rodriguez P, Strouboulis J, Vidal M. Proteomics analysis of Ring1B/Rnf2 interactors identifies a novel complex with the Fbxl10/Jhdm1B histone demethylase and the Bcl6 interacting corepressor. Mol Cell Proteomics. 2007;6(5):820-834.
37. Gearhart MD, Corcoran CM, Wamstad JA, Bardwell VJ. Polycomb group and SCF ubiquitin ligases are found in a novel BCOR complex that is recruited to BCL6 targets. Mol Cell Biol. 2006;26(18):6880-6889.
38. Lagarou A, et al. dKDM2 couples histone H2A ubiquitylation to histone H3 demethylation during Polycomb group silencing. Genes Dev. 2008;22(20):2799-2810.
39. Yuan W, Xu M, Huang C, Liu N, Chen S, Zhu B. H3K36 methylation antagonizes PRC2-mediated H3K27 methylation. J Biol Chem. 2011;286(10):7983- 7989.
40. Schmitges FW, et al. Histone methylation by PRC2 is inhibited by active chromatin marks. Mol Cell. 2011;42(3):330-341.
41. Di Tacchio L, et al. Histone lysine demethylase JARI-D1a activates CLOCK-BMAL1 and influences the circadian clock. Science. 2011;333(6051):1881- 1885.
42. Lopez-Bigas N, et al. Genome-wide analysis of the H3K4 histone demethylase RBP2 reveals a transcriptional program controlling differentiation. Mol Cell. 2008;31(4):520-530.
43. Peng JC, et al. Jarid2/Jumonji coordinates control of PRC2 enzymatic activity and target gene occupancy in pluripotent cells. Cell. 2009;139(7):1290-1302.
44. Grewal SS, Li L, Orian A, Eisenman RN, Edgar BA. Myc-dependent regulation of ribosomal RNA synthesis during Drosophila development. Nat Cell Biol. 2005;7(3):295-302.
45. Arabi A, et al. c-Myc associates with ribosomal DNA and activates RNA polymerase I transcription. Nat Cell Biol. 2005;7(3):303-310.
46. Birnbaum DJ, et al. Genome profiling of pancreatic adenocarcinoma. Genes Chromosomes Cancer. 2011;50(6):456-465.
47. Hamilton SR, Aaltonen LA, eds. Pathology and genetics of tumours of the digestive system. Lyon, France: IARC Press; 2000.
48. Hruban RH, et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol. 2001;25(5):579-586.